New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:37 EDTBIOCBiocept expands breast cancer offering
Biocept announced the launch of its estrogen receptor status testing on CTCs that will be performed at the Company's CLIA-certified and CAP-accredited laboratory. The launch of ER status testing, in conjunction with the company's HER2 receptor status test, will offer health care providers an additional testing option when a tumor biopsy is unavailable or unsafe. For patients with recurring or newly diagnosed metastatic breast cancer, accurate identification of hormone and HER2 receptors status plays a major role in treatment outcomes. The company said, "Our validation study for hormone status provided significant insights into hormone status as it relates to primary and metastatic breast cancers. We were able to correlate both concordance and discordance of primary biopsy tissue and metastatic biopsy tissue with the CTC status of estrogen receptors."
News For BIOC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
07:01 EDTBIOCBiocept gains patent protection in Hong Kong and Japan
Biocept announces the allowance of the patent detection or isolation of target molecules using a microchannel apparatus in Hong Kong and Japan. The patent issued as HK1135725 in Hong Kong and JP5824387 in Japan, and covers Biocept's microchannels for the capture of molecular targets, including circulating tumor cells and other rare cells, from blood and other biological fluids.
November 23, 2015
07:00 EDTBIOCBiocept secures agreements with preferred provider organization networks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use